A randomized phase II/III study of naptumomab estafenatox plus IFN-α versus IFN-α in advanced renal cell carcinoma.
Robert E. Hawkins
No relevant relationships to disclose
Martin Eric Gore
No relevant relationships to disclose
Yaroslav Shparyk
Research Funding - Active Biotech
Vladimir Bondar
Research Funding - Active Biotech
Oleg Gladkov
Research Funding - Active Biotech
Tosho Ganev
Research Funding - Active Biotech
Mihai Harza
Research Funding - Active Biotech
Serhii Polenkov
Research Funding - Active Biotech
Igor Bondarenko
Research Funding - Active Biotech
Petr A Karlov
Research Funding - Active Biotech
Oleg Karyakin
Research Funding - Active Biotech
Rustem Khasanov
Research Funding - Active Biotech
Gunnar Eric Hedlund
Employment or Leadership Position - Active Biotech
Stock Ownership - Active Biotech
Goran Forsberg
Employment or Leadership Position - Active Biotech
Stock Ownership - Active Biotech
Orjan Nordle
Employment or Leadership Position - Active Biotech
Stock Ownership - Active Biotech
Tim Eisen
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Pfizer; Roche
Stock Ownership - AstraZeneca
Honoraria - AVEO; Bayer; GlaxoSmithKline; Pfizer; Roche
Research Funding - Bayer; GlaxoSmithKline; Pfizer